Bengaluru, Karnataka, India, August 03, 2017:
The USFDA visit in May/June was a part of the regular periodic audits for a small molecule injectable. The company has responded to the regulator with a Corrective and Preventive Action Plan (CAPA) and is on track to implement them in a timely manner.
Please note Biocon has shared information related to this visit on July 31, 2017.
– Company Spokesperson
